Announcements Trials
Browse Landscape

Phase

Phase 2 17Phase 1/2 9Phase 1 4Phase EARLY_PHASE1 1Phase 3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma 1

Interventions

pembrolizumab 7Cyclophosphamide 5Metformin 4durvalumab 3Vincristine 3Radiation 3Imiquimod 3Fluorouracil 3antitumor A 2Testosterone 2Surveys and Questionnaires 2Rituximab 2Prednisone 2Positron Emission Tomography Computed Tomography 2Oxaliplatin 2Leucovorin 2Lapatinib 2Immunoglobulin G 2HhAntag691 2Doxorubicin 2Disulfides 2Cisplatin 2Biopsy 2xentuzumab 1tremelimumab 1ribociclib 1posaconazole 1pexidartinib 1perflutren 1pazopanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Has results × entinostat × Clear all
NCT03018249 2021-11-16

Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer

National Cancer Institute (NCI)

Phase EARLY_PHASE1 Completed
50 enrolled 12 charts
Gynecologic

FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡